https://www.reuters.com/business/health ... 023-12-05/
Laatste artikelen op Beursig.com
Also noteworthy is that pemvidutideâ€™s tolerability was reportedly better than that of other GLP 1 treatments. Finally, the drugâ€™s reduced LDL cholesterol more than two other popular GLP 1 drugs, semaglutide and tirzepatide.
Given these points, the $538 million market capitalization of ALT stock far undervalues the shares, while the company could easily become a takeover target.
https://www.nasdaq.com/articles/stocks- ... loss-drugs